« previous next »
Pages: [1]

Author Topic: (Abst.) Gray matter atrophy in MS despite clinical and lesion stability during Tysabri treatment  (Read 167 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9841
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Gray matter atrophy in MS despite clinical and lesion stability during Tysabri treatment
« on: December 23, 2018, 04:41:39 pm »
From PubMed, December 23, 2018--"Gray matter atrophy in multiple sclerosis despite clinical and lesion stability during natalizumab treatment":


https://www.ncbi.nlm.nih.gov/pubmed/30576361
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

Offline agate

  • Administrator
  • *****
  • Posts: 9841
  • MS diagnosed 1980
  • Location: Pacific Northwest
Re: (Abst.) Gray matter atrophy in MS despite clinical and lesion stability during Tysabri treatment
« Reply #1 on: January 17, 2019, 07:44:54 am »
Report to moderator   Logged
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.
Pages: [1]
« previous next »
 

Related Topics